AnaptysBio partners with Celgene to deliver antibody drug candidates
This article was originally published in Scrip
Executive Summary
Private biotechnology company AnaptysBio announced an agreement with Celgene on 9 April as its fifth partnership to develop novel antibodies using the San Diego firm's SHM-XEL platform.